Abstract Weight adjusted fixed dose subcutaneous unfractionated heparin (UFH) is one of the options for the treatment of deep vein thrombosis (DVT), but the degree of its anticoagulant effect has not been tested in India. This was a prospective observational study, conducted at a tertiary care hospital in South India between September 2012 and March 2014. DVT was diagnosed using compression ultrasonography. UFH was given as an initial loading dose of 333 U/kg followed by a maintenance dose of 250 U/kg twice daily subcutaneously. aPTT was done on day 2 and day 4 after 6 h of the morning dose of heparin. Patients were categorized based on aPTT ratios. Fifty five patients treated for proximal lower limb DVT had received UFH. Their median age was 41 years. DVT was secondary to malignancy, immobilisation or pro-coagulant state. No obvious etiology was found in 47 % of the patients. The mean aPTT on day 2 was 41.8 s and 51.7 s on day 4. The aPTT ratio was subtherapeutic in 63.6 % and therapeutic in 32.7 % of the patients on day 2. Five patients had adverse events in the hospital. Three patients died and two other patients had confirmed pulmonary embolism. Death was due to pulmonary embolism in one patient and metastatic malignancies in the other two. No bleeding manifestation had occurred. Caution is required in implementing this UFH regimen as this preliminary investigation has found predominantly subtherapeutic aPTT ratios during the initial phase of anticoagulation.
Introduction
Deep vein thrombosis (DVT) can lead to pulmonary embolism which can be fatal [1] . The annual incidence of DVT in the West is about 1 per 1000 population [2] . Its occurrence is the East has been shown to be similar [3] , which may be true for India too. The mainstay of treatment involves bridging anticoagulation therapy from a parenteral heparin-type anticoagulant to a vitamin K antagonist such as warfarin [4] . Low molecular weight heparin (LMWH) is the preferred parenteral anticoagulant during the initial treatment [5] . Unfractionated heparin (UFH) when used needs to be given intravenously with the monitoring of activated partial thromboplastin time (aPTT) [6] . UFH used subcutaneously has been found to be non-inferior to LMWH in the treatment of DVT when used as a weight adjusted regimen [7] . The dose used was 333 U/kg subcutaneously as a loading dose followed by 250 U/kg subcutaneously twice daily. This regimen does not require aPTT monitoring. This attribute and the low cost make it one of the preferred choices in our settings. But, the degree of anticoagulant effect of this regimen has not been tested in India. Hence this study was designed to assess the adequacy of anticoagulation with this fixed dose weight adjusted regimen.
Materials and Methods
This was a prospective observational study, conducted at a tertiary care hospital in South India between September 2012 and March 2014. It was approved by the Institute Ethics Committee. Informed consent was obtained from all individual participants included in the study. All consecutive patients who presented to the Department of Medicine with signs and symptoms of DVT were screened with compression ultrasonography and the patients with proximal lower limb DVT were included in the study. Each patient's complete history and examination were recorded in a structured proforma. Baseline investigations included haemogram, prothrombin time, chest roentgenogram, ultrasonography of abdomen. CT pulmonary angiogram (CTPA) was done in patients with suspected pulmonary embolism. Patients were treated with either weight adjusted fixed dose UFH or LMWH as per the treating unit's decision. The characteristics of patients treated with UFH have been reported here. UFH was given with an initial loading dose of 333 U/kg followed by a maintenance dose of 250 U/kg twice daily given subcutaneously. Oral anticoagulation with warfarin was started on the day of starting anticoagulation with heparin. aPTT was done on day 2 and day 4 in patients who were receiving UFH, after 6 h of the morning dose of heparin. This was to record the level of anticoagulation. The dose of heparin was not altered based on the aPTT values. Patients were categorized into having aPTT ratio in therapeutic range (1.5-2.5 times the control) or sub-therapeutic (less than 1.5 times the control) or supratherapeutic aPTT ratio (more than 2.5 times the control) on respective days. aPTT time was done using Stago semi-automated coagulometer, Diagnostica Stago, Inc., France. The reagents used were C.K. prest (cephalin, kaolin) and Calcium chloride (0.025 M). The test was done in duplicate. Patients were followed up till 3 months after discharge. Outcomes assessed were that of pulmonary embolism, DVT recurrence, bleeding and death in hospital and at 3 months after discharge. The data has been summarised using appropriate descriptive statistics. Stacked bar graphs have been used to depict aPTT ratios.
Results
Sixty patients with proximal lower limb DVT had been admitted between September 2012 and March 2014. The diagnosis of DVT had been made by compression ultrasonography in all the patients. Fifty five patients had been treated with weight adjusted fixed dose subcutaneous UFH and five patients had received LMWH. The clinical features of the patients who had received UFH have been described below ( Table 1) .
The median age of the patients was 41 years (IQR 27-55). Thirty two patients (58 %) were women. Thirty nine patients (71 %) belonged to Tamil Nadu and rest of them were from Pondicherry. Median duration of symptoms at presentation was 6 days. One of the patients had pulmonary embolism (confirmed by CTPA) at diagnosis. DVT was secondary to a malignancy in nine patients (16 %), immobilisation either post-surgery or after trauma in eight patients (15 %). Six (11 %) patients were postpartum. Antiphospholipid syndrome was diagnosed in 4 (7 %) patients. DVT could be attributed to intake of oral contraceptive pills in two (4 %) patients. No obvious etiology was noted in 26 (47 %) patients.
Activated Partial Thromboplastin Time
All the patients had been managed in the hospital for a minimum of 5 days. The average duration of hospital stay was 6.3 days. The mean starting and maintenance dose of heparin were 19360 IU (SD 3345) and 14490 IU (SD 2525) respectively. All patients had simultaneously received oral anticoagulation with warfarin (5 mg) from the first day onwards. aPTT levels were done on the second day and fourth day to assess the adequacy of the anticoagulation (Fig. 1) . The mean aPTT on day 2 was 41.8 s (SD 18.5). The mean control aPTT on day 2 was 28.8 s (SD 2.25). The aPTT ratio was subtherapeutic in 35 of 55 patients (63.6 %). It was therapeutic in 18 (32.7 %) patients and in two patients it was supratherapeutic. The mean aPTT on day 4 was 51.7 s (SD 18.95). The mean control aPTT on day 4 was 29.03 s (SD 1.87). The aPTT ratio was subtherapeutic in 15 of 55 patients (27.7 %), therapeutic in 37 (67 %) patients and supratherapeutic in three patients. 
In Hospital Outcome
Fifty four patients had DVT alone and one patient had DVT with pulmonary embolism at presentation. The patient with pulmonary embolism was hemodynamically stable and he had been treated with weight adjusted subcutaneous UFH, with which he had improved. Five patients had adverse events. Three patients died and two other patients had confirmed pulmonary embolism. Of the three patients who had died, two patients had metastatic malignancies and one patient had died because of suspected pulmonary embolism. The patients with malignancies died of sepsis secondary to cellulitis and pyelonephritis. The patient with suspected pulmonary embolism had developed DVT following immobilisation for a fracture femur. In the hospital, on day 5 she developed breathlessness and tachycardia. She had deteriorated rapidly, developed hypotension and died. Pulmonary embolism could not be confirmed by CTPA. Her APTT on day 2 and 4 were 50.6 s (1.6 times the control) and 62.3 s (2 times the control) respectively. The two other patients with confirmed pulmonary embolism improved with treatment. One of these patients had developed hypotension and had received thrombolytic treatment with streptokinase. None of the patients had experienced any bleeding manifestation.
Outcome at Three Months
The patients were followed for 3 months. Of 55 patients, 37 patients were on follow up, 13 patients were lost to follow up and five patients had died. 32 patients were on regular follow up and were compliant with treatment and five patients were not. There was recurrence of DVT in one patient. This patient had not been compliant with oral anticoagulation and had developed DVT of the other limb at 3 months of discharge. DVT had resolved by ultrasonography in nine patients. Three patients had pulmonary embolism (diagnosed in hospital). Five patients had died in total, three in the hospital and two after discharge. The two patients who died at home had metastatic malignancies. None of the patients had any bleeding manifestation.
Discussion
The degree of anticoagulation achieved by weight adjusted fixed dose UFH has been assessed in this study. 64 and 28 % of the patients had subtherapeutic aPTT ratios on day 2 and on day 4 respectively. The aPTT levels differed on the 2 days it had been measured. The day 4 aPTT being more prolonged than the day 2 aPTT, a trend similar to that observed by Kearon C et al. [8] . This could have been due to the simultaneous use of the oral anticoagulant. The aPTT can increase by 20 s with every increase in the INR of 1.0 [8] .
The proportion of patients with subtherapeutic aPTT ratio was higher than those seen in the studies done by Kearon C et al. and Munsamy JI et al., which was 20 % each after an average of 2.8 and 3.5 days after starting heparin respectively as compared to 64 % on day 2 in this study [7, 9] . Variation in aPTT values occur depending on the reagents and instruments used [10] . But the values were consistently lower here. No bleeding manifestations had been noted in keeping with the levels of aPTT achieved. 5.5 % of patients developed pulmonary embolism during the hospital stay. The same was 0.3 % during the first 10 days in the study by Kearon C et al. [7] . Hence, subcutaneous UFH led to subtherapeutic aPTT and a trend towards increased occurrence of pulmonary embolism. It is important to note that the current guidelines have recommended against the use of fixed dose UFH in acute VTE [6] . Though cheap initially, it may prove costly if any patient develops PTE.
The limitation of the study was the sole consideration of the aPTT ratio between 1.5 and 2.5 as the therapeutic target. Prolonged aPTT does not correlate with the risk of bleeding and similarly subtherapeutic aPTT does not correlate with recurrent thromboembolism [7] . Estimating heparin levels using anti-Xa assay has been studied as an alternative monitoring method but it too has its limitations [10] .
In conclusion, even though the fixed dose weight adjusted subcutaneous UFH regimen has been proved to be non-inferior to LMWH, caution is required before extrapolating it to our settings as this preliminary investigation has found predominantly subtherapeutic aPTT ratios during the initial phase of anticoagulation. 
